Maximize your thought leadership

Unbuzzd Wellness Launches $5 Million Regulation D Offering to Fuel Growth and IPO Ambitions

By FisherVista

TL;DR

Quantum BioPharma's Unbuzzd Wellness Inc. offers a unique investment opportunity with an anti-dilution provision protecting shareholders until a $1 billion valuation is reached.

Unbuzzd Wellness Inc. is conducting a Regulation D 506(c) offering to raise up to US$5 million, utilizing partnerships with MZ Digital and Dealmaker for campaign management.

Unbuzzd's beverage aims to improve health by accelerating alcohol metabolism and reducing hangover symptoms, contributing to a healthier lifestyle and societal well-being.

Unbuzzd's innovative beverage and its funding strategy mark a significant step towards addressing alcohol misuse with a potential IPO on the horizon.

Found this article helpful?

Share it with your network and spread the knowledge!

Unbuzzd Wellness Launches $5 Million Regulation D Offering to Fuel Growth and IPO Ambitions

Unbuzzd Wellness Inc., a portfolio company of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), has announced the launch of a Regulation D 506(c) offering aimed at raising up to $5 million. This strategic move is designed to fund the company's growth initiatives and advance its preparations for a potential initial public offering (IPO). The offering is notable for its inclusion of both traditional and cryptocurrency investment options, facilitated through partnerships with MZ Digital and Dealmaker.

The capital raise is structured in a manner that prevents dilution of Quantum BioPharma shareholders, thanks to an anti-dilution provision that secures the company's 25% ownership stake in Unbuzzd until the beverage company achieves a $1 billion valuation. Unbuzzd is the creator of unbuzzd(TM), a beverage formulated to accelerate alcohol metabolism, enhance mental clarity, and mitigate hangover symptoms. The company's CEO, John Duffy, emphasized that the funds from this offering will be instrumental in expanding direct-to-consumer sales, distributor networks, and retail presence. Gerry David, Board Co-Chair, highlighted the offering as a pivotal step towards positioning Unbuzzd for a future IPO.

Quantum BioPharma, the parent company, is a biopharmaceutical firm with a focus on developing innovative solutions for neurodegenerative and metabolic disorders, including alcohol misuse. Its subsidiary, Lucid Psycheceuticals Inc., is at the forefront of researching Lucid-MS, a patented compound aimed at addressing myelin degradation in multiple sclerosis. Quantum BioPharma's strategic investments, including its stake in Unbuzzd, underscore its commitment to fostering advancements in both pharmaceutical and wellness sectors. For more details on Quantum BioPharma's initiatives, visit https://ibn.fm/QNTM.

This development is significant for investors and the biotech industry, as it represents a convergence of traditional biopharmaceutical research with innovative wellness products. The offering not only provides a unique investment opportunity but also highlights the growing trend of cryptocurrency in funding rounds. For further information on Unbuzzd and its products, visit https://www.unbuzzd.com.

blockchain registration record for this content
FisherVista

FisherVista

@fishervista